免疫治疗时代肿瘤治疗反应评估的多模态影像学方法
本文综述了肺癌免疫治疗中各种肿瘤反应模式,讨论了CT和18F-氟脱氧葡萄糖PET在肺癌领域的定量方法,并探讨了MRI和non-FDG PET示踪剂等新兴技术;指出影像学在解剖影像学反应(CT/MRI)和分子变化(PET)中均至关重要,最后介绍了整合影像与非影像数据的多模态方法及未来方向。
要点
- 免疫治疗反应模式不同于传统化疗和靶向治疗,部分患者表现为现有测量标准无法判断的独特模式。
- 免疫治疗反应监测的难点包括真实反应与假性反应的鉴别。
- 影像学在解剖影像学反应(CT/MRI)和分子变化(PET)评估中均具有重要作用。
核心结论
- 免疫治疗为肺癌治疗带来显著进步,但其治疗反应模式与传统治疗不同,部分患者表现为现有测量标准无法判断的独特反应模式,影像学在解剖和分子层面评估治疗反应中均至关重要,整合影像与非影像数据的多模态方法是有前景的发展方向。
研究设计与样本
- 综述,围绕肺癌免疫治疗,概述肿瘤反应模式,讨论CT和18F-FDG PET的定量方法,并探讨MRI和non-FDG PET示踪剂等新兴技术。
临床应用与阅片要点
- 使用CT和PET评估治疗反应时需考虑多个方面。
- 免疫治疗反应监测中需鉴别真实反应与假性反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Immunotherapy is likely the most remarkable advancement in lung cancer treatment during the past decade. Although immunotherapy provides substantial benefits, their therapeutic responses differ from those of conventional chemotherapy and targeted therapy, and some patients present unique immunotherapy response patterns that cannot be judged under the current measurement standards. Therefore, the response monitoring of immunotherapy can be challenging, such as the differentiation between real response and pseudo-response. This review outlines the various tumor response patterns to immunotherapy and discusses methods for quantifying computed tomography (CT) and 18 F-fluorodeoxyglucose positron emission tomography (PET) in the field of lung cancer. Emerging technologies in magnetic resonance imaging (MRI) and non-FDG PET tracers are also explored. With immunotherapy responses, the role for imaging is essential in both anatomical radiological responses (CT/MRI) and molecular changes (PET imaging). Multiple aspects must be considered when assessing treatment responses using CT and PET. Finally, we introduce multimodal approaches that integrate imaging and nonimaging data, and we discuss future directions for the assessment and prediction of lung cancer responses to immunotherapy.
引用
- Lee G, Moon SH, Kim JH, et al. Multimodal Imaging Approach for Tumor Treatment Response Evaluation in the Era of Immunotherapy. Invest Radiol. 2024. PMID: 39018248. doi:10.1097/RLI.0000000000001096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。